Essure®器械移除后的临床改善:一项系统综述。

IF 1.9 4区 医学 Q3 OBSTETRICS & GYNECOLOGY European Journal of Contraception and Reproductive Health Care Pub Date : 2023-08-01 DOI:10.1080/13625187.2023.2236741
Chloe Miguet-Bensouda, Francois Parant, Guillaume Grenet, Emanuele Cerruto, Erdogan Nohuz, Gautier Chene
{"title":"Essure®器械移除后的临床改善:一项系统综述。","authors":"Chloe Miguet-Bensouda,&nbsp;Francois Parant,&nbsp;Guillaume Grenet,&nbsp;Emanuele Cerruto,&nbsp;Erdogan Nohuz,&nbsp;Gautier Chene","doi":"10.1080/13625187.2023.2236741","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Essure® implant is a permanently implanted minimally invasive birth control device for women (female sterilisation) widely used between 2002 and 2018. Many adverse events were reported by patients. Increasingly removal procedures have been performed in symptomatic patients. However, there is a lack of in-depth studies on clinical improvement after Essure® removal. We aimed to review all clinical studies about symptoms and quality of life (QoL) after removal procedures.</p><p><strong>Materials and methods: </strong>A review of literature in electronic search in Medline and Embase databases from January 2002 to January 2022 using the following keywords: Essure; Essure removal; quality of life; symptomatology improvement.</p><p><strong>Results: </strong>Out of 764 articles in the initial database, 18 clinical studies were eligible for inclusion in our literature review. Overall clinical improvement rates after removal ranged from 21% to 98%. All symptoms were less frequent after Essure® removal, although with large discrepancies between studies. Lack of improvement was reported between 1% to 15% of patients. Rate of patients with improvement of QoL after removal ranged from 58 to 98%. The pain was reported as significantly reduced after the surgery.</p><p><strong>Conclusions: </strong>In the available literature, Essure® removal in symptomatic patients may improve symptoms and quality of life. This should be discussed in the benefits and risks ratio before deciding on the best option of management.</p>","PeriodicalId":50491,"journal":{"name":"European Journal of Contraception and Reproductive Health Care","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical improvement after Essure® devices removal: a systematic review.\",\"authors\":\"Chloe Miguet-Bensouda,&nbsp;Francois Parant,&nbsp;Guillaume Grenet,&nbsp;Emanuele Cerruto,&nbsp;Erdogan Nohuz,&nbsp;Gautier Chene\",\"doi\":\"10.1080/13625187.2023.2236741\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Essure® implant is a permanently implanted minimally invasive birth control device for women (female sterilisation) widely used between 2002 and 2018. Many adverse events were reported by patients. Increasingly removal procedures have been performed in symptomatic patients. However, there is a lack of in-depth studies on clinical improvement after Essure® removal. We aimed to review all clinical studies about symptoms and quality of life (QoL) after removal procedures.</p><p><strong>Materials and methods: </strong>A review of literature in electronic search in Medline and Embase databases from January 2002 to January 2022 using the following keywords: Essure; Essure removal; quality of life; symptomatology improvement.</p><p><strong>Results: </strong>Out of 764 articles in the initial database, 18 clinical studies were eligible for inclusion in our literature review. Overall clinical improvement rates after removal ranged from 21% to 98%. All symptoms were less frequent after Essure® removal, although with large discrepancies between studies. Lack of improvement was reported between 1% to 15% of patients. Rate of patients with improvement of QoL after removal ranged from 58 to 98%. The pain was reported as significantly reduced after the surgery.</p><p><strong>Conclusions: </strong>In the available literature, Essure® removal in symptomatic patients may improve symptoms and quality of life. This should be discussed in the benefits and risks ratio before deciding on the best option of management.</p>\",\"PeriodicalId\":50491,\"journal\":{\"name\":\"European Journal of Contraception and Reproductive Health Care\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2023-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Contraception and Reproductive Health Care\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/13625187.2023.2236741\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Contraception and Reproductive Health Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13625187.2023.2236741","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:Essure®植入物是一种永久性植入的女性微创节育装置(女性绝育),在2002年至2018年期间广泛使用。患者报告了许多不良事件。越来越多的有症状的患者进行了切除手术。然而,目前缺乏对去除Essure®后临床改善的深入研究。我们的目的是回顾所有关于切除手术后症状和生活质量(QoL)的临床研究。材料与方法:回顾2002年1月至2022年1月在Medline和Embase数据库中电子检索的文献,使用以下关键词:Essure;确保清除;生活质量;症状的改善。结果:在初始数据库的764篇文章中,有18篇临床研究符合纳入我们的文献综述。切除后的总体临床改善率为21%至98%。虽然研究之间存在很大差异,但所有症状在去除Essure®后都较少见。1%至15%的患者报告缺乏改善。术后患者生活质量改善率为58% ~ 98%。据报道,手术后疼痛明显减轻。结论:在现有文献中,对有症状的患者进行Essure®去除可改善症状和生活质量。在决定最佳管理方案之前,应该在收益和风险比中讨论这一点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Clinical improvement after Essure® devices removal: a systematic review.

Purpose: Essure® implant is a permanently implanted minimally invasive birth control device for women (female sterilisation) widely used between 2002 and 2018. Many adverse events were reported by patients. Increasingly removal procedures have been performed in symptomatic patients. However, there is a lack of in-depth studies on clinical improvement after Essure® removal. We aimed to review all clinical studies about symptoms and quality of life (QoL) after removal procedures.

Materials and methods: A review of literature in electronic search in Medline and Embase databases from January 2002 to January 2022 using the following keywords: Essure; Essure removal; quality of life; symptomatology improvement.

Results: Out of 764 articles in the initial database, 18 clinical studies were eligible for inclusion in our literature review. Overall clinical improvement rates after removal ranged from 21% to 98%. All symptoms were less frequent after Essure® removal, although with large discrepancies between studies. Lack of improvement was reported between 1% to 15% of patients. Rate of patients with improvement of QoL after removal ranged from 58 to 98%. The pain was reported as significantly reduced after the surgery.

Conclusions: In the available literature, Essure® removal in symptomatic patients may improve symptoms and quality of life. This should be discussed in the benefits and risks ratio before deciding on the best option of management.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.70
自引率
11.80%
发文量
63
审稿时长
>12 weeks
期刊介绍: The Official Journal of the European Society of Contraception and Reproductive Health, The European Journal of Contraception and Reproductive Health Care publishes original peer-reviewed research papers as well as review papers and other appropriate educational material.
期刊最新文献
A randomised double-blind trial to determine the bleeding profile of the prolonged-release contraceptive dienogest 2 mg/ethinylestradiol 0.02 mg versus an immediate-release formulation of drospirenone 3 mg/ethinylestradiol 0.02 mg. Medical termination of pregnancy: people's expectations and experiences in the Netherlands. Neighbourhood environment and early menarche among adolescent girls of five countries. Postpartum contraception provision across Europe: preliminary findings from a multi country survey. Response to Daungsupawong and Wiwanitkit's Letter to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1